The Relation of Baseline Serum Albumin with the Duration of Neutropenia after Induction Chemotherapy in Adult Acute Leukaemia
DOI:
https://doi.org/10.51253/pafmj.v73i6.5970Keywords:
Albumin,, Induction chemotherapy leukaemia, Neutropenia, Nutritional statusAbstract
Objective: To determine the relation of baseline serum albumin levels with the duration of neutropenia after induction
chemotherapy in acute leukaemia.
Study design: Prospective longitudinal study.
Place and Duration of Study: Department of Medical Oncology, Combined Military Hospital, Rawalpindi Pakistan, Dec 2018 and Dec 2020.
Methodology: Ninety-one patients with newly diagnosed acute leukaemia who were planned to receive induction
chemotherapy were included. Before starting chemotherapy, blood counts and serum albumin levels were determined in each patient. The tests were monitored during treatment, and the duration of days when the patient experienced neutropenia was noted.
Results: The mean age of participants was 29.70±9.50 years. 64(70.3%) were males and 27(29.7 %) were female. At
presentation, the mean white blood cell (WBC) count in peripheral blood was 16.70±39.60 x109/L. 29 (31.9%) patients had
hypoalbuminemia with serum albumin <3.5g/dL, while 62 (68.1%) patients had normal serum albumin ≥3.5g/dL. The mean
duration of neutropenia in the Low Albumin Group was 8.20±5.30 days. The mean duration of neutropenia in Normal
Albumin (≥3.5g/dL) Group was 7.50±6.30 days. There was no Statistical difference between low serum albumin and the
duration of neutropenia (p-value 0.605).
Conclusion: This study shows that the pre-chemotherapy serum albumin level has no significant relation with the duration of neutropenia experienced by the patient after induction chemotherapy of acute leukaemia.
Downloads
References
Fialkow PJ, Janssen J, Bartram CR. Clonal remissions in acutenonlymphocytic leukemia: evidence for a multistep pathogenesisof the malignancy. Blood 1991; 77(7): 1415-1417.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2021. CA CancerJ Clin 2017; 71(1): 7-33.https://doi.org/10.3322/caac.21654.
Hwang Sang Me. Classification of Acute Myeloid Leukemia.Blod Res 2020; 55(Suppl): S1–S4.https://doi.org/10.5045/br.2020.S001.
Watson RR, Mahadevan D, Hagiwara S. multidisciplinarynutritional support in hematopoietic stem celltransplant.In:Handbook of Nutrition and diet in leukemia and blood diseasetherapy. Wageningen, The Netherlands, Netherlands:Wageningen Academic Publishers; 2016.
Braga CC, Taplitz RA. Clinical implications of febrile neutropenia guidelines in the cancer patient population. J Oncol Prac
; 15(1): 25–26. https://doi.org/10.1200/JOP.18.00718.
Logan C, Koura D, Taplitz R. Updates in infection risk and management in acute leukemia. Hematology 2020; 2020(1): 135–
https://doi.org/10.1182/hematology.2020000098.
Vijenthira A, Chiu N, Jacobson D, Freedman Z, Cheung MC,Goddard S, et al. Predictors of intensive care unit admission in
patients with hematologic malignancy. Sci Rep 2020; 10(1): 1–9.https://doi.org/10.1038/s41598-020-78114-7.
Wang XJ, Wong M, Hsu LY, Chan A. Costs associated withfebrile neutropenia in solid tumor and lymphoma patients – an
observational study in Singapore. BMC Health Serv Res 2014; 14:434. https://doi.org/10.1186/1472-6963-14-434.
Malihi Z, Kandiah M, Chan YM, Esfandbod M, Vakili M,Hosseinzadeh M, et al. The effect of dietary intake changes on
nutritional status in acute leukaemia patients after first inductionchemotherapy. Eur J Cancer Care 2015; 24(4): 542-552.
https://doi.org/10.1111/ecc.12262.
Nganthavee V, Phutthasakda W, Atipas K, Tanpong S,Pungprasert T, Dhirachaikulpanich D, et al. High incidence of
invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and
treatment outcomes. Support Care Cancer 2019; 27(9): 3613-3622.https://doi.org/10.1007/s00520-019-04720-5.
Pattnaik J, Kayal S, Dubashi B, Basu D, Vinod KV, Nandeesha H,et al. Profile of anemia in acute lymphoblastic leukemia patients on maintenance therapy and the effect of micronutrient supplementation. Support Care Cancer 2020; 28(2): 731-738.https://doi.org/10.1007/s00520-019-04862-6.
Jaime-Pérez JC, García-Arellano G, Herrera-Garza JL, MarfilRivera LJ, Gómez-Almaguer D. Revisiting the complete blood
count and clinical findings at diagnosis of Childhood Acute Lymphoblastic Leukemia: 10-Year experience at a single center.
Hematol Transfus Cell Ther 2019; 41(1): 57-61. https://doi.org/10.1016/j.htct.2018.05.010.
Keller U. Nutritional Laboratory Markers in Malnutrition. J ClinMed 2019; 8(6): 775. https://doi.org/10.3390/jcm8060775.
Morrison VA. Infections in patients with leukemia andlymphoma. Cancer Treat Res 2014; 161: 319-349.
https://doi.org/10.1007/978-3-319-04220-6_11.
Komrokji RS, Kharfan-Dabaja MA, Price SL, Wetzstein GA, List AF, Fernandez HF, et al. Albumin is a prognostic factor for
response and overall survival in relapsed or refractory acute myeloid leukemia (AML). Blood 2009; 114(22): 4685–4685.
Khan AM, Lancet JE, Kharfan-Dabaja MA, Al Ali NH, List AF, Komrokji RS. Albumin is a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML). Am J Hematol 2012 Nov; 87(11): 1006-1009.
https://doi.org/10.1002/ajh.23303.
Esfahani A, Ghoreishi Z, Abedi Miran M, Sanaat Z, OstadrahimiA, Eivazi Ziaei J, et al. Nutritional assessment of patients withacute leukemia during induction chemotherapy: association with hospital outcomes. Leuk Lymphoma 2014; 55(8): 1743-1750.https://doi.org/10.3109/10428194.2013.853766.
Ghafoor T, Ahmed S, Khalil S, Farah T. Impact of Malnutritionon Treatment Outcome of Paediatric Acute Myeloid Leukemia. J Coll Physicians Surg Pak 2020; 30(10): 1021-1025.https://doi.org/10.29271/jcpsp.2020.10.1021.
Downloads
Published
Issue
Section
How to Cite
